A preventive treatment for dementia may proceed to clinical trials after successful animal testing.
The US-led research is looking to develop effective immunotherapy via a new vaccine to remove ‘brain plaque’ and tau protein aggregates linked to Alzheimer’s disease.
Recent success in bigenic mice models supports progression to human trials in years to come, the researchers say.
A new paper in the journal Alzheimer’s Research & Therapy paves the way for more work in 2020, with medical researchers at the Institute for Molecular Medicine and University of California, Irvine (UCI) working with a successful vaccine formulated on adjuvant developed by Flinders University Professor Nikolai Petrovsky in South Australia.
The latest research aims to come up with a new treatment to remove accumulated beta-amyloid (A?) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline in Alzheimer’s disease.
Alzheimer’s disease (AD) is the leading cause of age-related dementia, affecting about 5.7 million people in the US. Major challenges in AD include the lack of effective treatments, reliable biomarkers, or preventive strategies.
Professor of the Institute for Molecular Medicine Anahit Ghochikyan and colleagues, Associate Professors Hvat Davtyan and Mathew Blurton-Jones from UCI, and other co-authors tested the universal MultiTEP platform-based vaccines formulated in the adjuvant developed at Professor Petrovsky’s Australian lab.
The possible new therapies were tested in bigenic mice with mix A? and tau pathologies.
“Taken together, these findings warrant further development of this dual vaccination strategy based on the MultiTEP technology for ultimate testing in human Alzheimer’s disease,” the lead authors Professor Ghochikyan and Blurton-Jones conclude.
Professor Petrovsky says the Advax adjuvant method is a pivotal system to help take the combination MultiTEP-based A?/tau vaccines therapy, as well as separate vaccines targeting these pathological molecules, to clinical trials – perhaps within two years.
“Our approach is looking to cover all bases and get past previous roadblocks in finding a therapy to slow the accumulation of A?/tau molecules and delay AD progression in a the rising number of people around the world,” says Professor Petrovsky, who will work in the US for the next three months.
Several promising drug candidates have failed in clinical trials so the search for new preventions or therapies continues.
A recent report on human monoclonal antibody, aducanumab, showed that high dose of this antibody reduced clinical decline in patients with early AD as measured by primary and secondary endpoints.
However, it is obvious that it could not be used as a preventive measure in healthy subjects due to the need for frequent (monthly) administration of high concentrations of immunotherapeutic.
Professor Ghochikyan says there is a pressing need to keep searching for new preventive vaccine to delay AD and slow down progression of this devastating disease.
The new combined vaccination approach could potentially be used to induce strong immune responses to both of the hallmark pathologies of AD in a broad population base of vaccinated subjects with high MHC (major histocompatibility complex) class II gene polymorphisms, the new paper concludes.
Go deeper with Bing News on:
- Aquin: Call on lawmakers to continue fight against Alzheimer'son March 15, 2020 at 4:00 am
For the past 33 years, people from every state have traveled to Washington, D.C., to advocate for a treatment, a cure and a vaccine for Alzheimer’s Disease. People with the disease, family members and ...
- Flattening the Covid-19 curve & primary care physicians on dementiaon March 11, 2020 at 9:07 am
Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals People ‘shed’ high levels of coronavirus, study finds, but… People ‘shed’ high levels of coronavirus ...
- New system will streamline development of tuberculosis vaccineson March 5, 2020 at 6:01 am
Scientists from James Cook University's Australian Institute of Tropical Health and medicine (AITHM) have developed a system to improve the development of tuberculosis (TB) vaccines. Senior ...
- Maine voters consider U-turn on vaccine exemptionson March 3, 2020 at 5:09 am
As Mainers head to the polls on Super Tuesday for the presidential primary, they also will decide another issue: vaccine requirements. A statewide referendum asks if voters want to overturn a new ...
- Donald Trump demands coronavirus vaccine in 'two months' and offers pharma chiefs SEATTLE for trialson March 2, 2020 at 2:49 pm
We're working very hard to expedite the longer process of developing a vaccine. We're also moving with maximum speed to develop a therapy so that we can help people recover as quickly as possible ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Coronavirus vaccine funding announcement as number of Queensland COVID-19 cases riseon March 21, 2020 at 9:29 pm
The Queensland Premier Annastacia Palaszczuk has announced a $17 million package to fast-track a coronavirus vaccine developed in the state.
- Coronavirus vaccine trials: Chinese volunteers recount their experienceson March 21, 2020 at 8:03 pm
108 people aged 18-60 from Wuhan have been injected with a potential vaccine developed by a Chinese pharmaceutical firm and the military One says that by taking part she can ‘rise above the simple ...
- Sick parents with 102° fevers denied coronavirus test, as son begins vaccine trialon March 21, 2020 at 7:25 pm
As Pennsylvania parents stayed home with Coronavirus symptoms, their son participated in a test that could change the course of a global pandemic.
- Vaccine scientist: ‘Everything is so new in dealing with this coronavirus’on March 21, 2020 at 1:51 pm
Hanneke Schuitemaker, who is leading a team working on a Covid-19 vaccine, tells of the latest developments and what needs to be done now ...
- 'I Wanted To Do Something,' Says Mother Of 2 Who Is First To Test Coronavirus Vaccineon March 21, 2020 at 4:44 am
When Jennifer Haller heard that researchers were looking for volunteers to be injected with an experimental coronavirus vaccine, the Seattle mother of two rolled up her sleeve. Well, not literally.